Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review.

ABSTRACT:

Background

Aducanumab, a new monoclonal antibody that targets β-amyloid aggregates, has been granted conditional approval by the U.S. FDA for treatment of mild Alzheimer's disease (AD). The approval of this drug without a confirmed significant clinical impact has resulted in several debates.

Objective

In this narrative review, aducanumab approval-related controversy, the drug's pharmacokinetics and pharmacodynamic characteristics, evidence from the efficacy and safety trials of aducanumab, implications of the drug approval, and the future directions in the management of patients with AD are summarized.

Methods

Using relevant keywords, Google Scholar, Web of Science, and MEDLINE databases and manufacturer's website were searched.

Results

Infusion of aduca

SUBMITTER: Beshir SA 

PROVIDER: S-EPMC8926483 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature